Santerre Henriksen A - Search Results

1

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.

Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C; ARTEMIS Study Investigators. Santerre Henriksen A, et al. Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14. Microbiol Spectr. 2024. PMID: 38483164 Free PMC article.

2

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis.

Longshaw C, Santerre Henriksen A, Dressel D, Malysa M, Silvestri C, Takemura M, Yamano Y, Baba T, Slover CM. Longshaw C, et al. Among authors: santerre henriksen a. Microbiol Spectr. 2023 Dec 12;11(6):e0237123. doi: 10.1128/spectrum.02371-23. Epub 2023 Nov 15. Microbiol Spectr. 2023. PMID: 37966262 Free PMC article.

3

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic.

Giannella M, Verardi S, Karas A, Abdel Hadi H, Dupont H, Soriano A, Santerre Henriksen A, Cooper A, Falcone M; ARES Study Group. Giannella M, et al. Among authors: santerre henriksen a. Open Forum Infect Dis. 2023 Jul 4;10(7):ofad329. doi: 10.1093/ofid/ofad329. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37496600 Free PMC article.

4

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials.

Longshaw C, Roger E, Santerre Henriksen A, Baba T, Nguyen S, Yamano Y. Longshaw C, et al. Among authors: santerre henriksen a. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0110022. doi: 10.1128/aac.01100-22. Epub 2022 Sep 12. Antimicrob Agents Chemother. 2022. PMID: 36094308 Free PMC article. No abstract available.

5

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.

Longshaw CM, Santerre Henriksen A, Slover C, Yamano Y, Karas JA. Longshaw CM, et al. Among authors: santerre henriksen a. J Antimicrob Chemother. 2022 Sep 30;77(10):2895-2896. doi: 10.1093/jac/dkac277. J Antimicrob Chemother. 2022. PMID: 35971761 Free PMC article. No abstract available.

6

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016-19).

Canton R, Hamed K, Wiktorowicz T, Redder N, Jemmely N, Quevedo J, Santerre Henriksen A. Canton R, et al. Among authors: santerre henriksen a. JAC Antimicrob Resist. 2022 Mar 24;4(2):dlac030. doi: 10.1093/jacamr/dlac030. eCollection 2022 Apr. JAC Antimicrob Resist. 2022. PMID: 35350131 Free PMC article.

7

In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.

Candel FJ, Santerre Henriksen A, Longshaw C, Yamano Y, Oliver A. Candel FJ, et al. Among authors: santerre henriksen a. Clin Microbiol Infect. 2022 Mar;28(3):447.e1-447.e6. doi: 10.1016/j.cmi.2021.07.018. Epub 2021 Jul 21. Clin Microbiol Infect. 2022. PMID: 34298176 Free article.

8

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France.

Naas T, Lina G, Santerre Henriksen A, Longshaw C, Jehl F. Naas T, et al. Among authors: santerre henriksen a. JAC Antimicrob Resist. 2021 Jun 14;3(2):dlab081. doi: 10.1093/jacamr/dlab081. eCollection 2021 Jun. JAC Antimicrob Resist. 2021. PMID: 34223140 Free PMC article.

9

Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates.

Antonelli A, Giani T, Coppi M, Di Pilato V, Arena F, Colavecchio OL, Conte V, Santerre Henriksen A, Rossolini GM; MRSA-HAP Study Group. Antonelli A, et al. Among authors: santerre henriksen a. J Antimicrob Chemother. 2019 Dec 1;74(12):3453-3461. doi: 10.1093/jac/dkz371. J Antimicrob Chemother. 2019. PMID: 31652323

10

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.

Scheeren TWL, Welte T, Saulay M, Engelhardt M, Santerre-Henriksen A, Hamed K. Scheeren TWL, et al. Among authors: santerre henriksen a. BMC Infect Dis. 2019 Feb 26;19(1):195. doi: 10.1186/s12879-019-3820-y. BMC Infect Dis. 2019. PMID: 30808293 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page